Acute, reversible pumonary hypertension associated with cocaine use

Collazos, Julio; Martínez, Eduardo; Fernández, A; Mayo, José

doi:10.1016/s0954-6111(96)90160-2

Cited by 29 publications

(15 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multiple studies have highlighted the occurrence of PAH in current and former cocaine users. 390,391 Despite the widespread use of various compounds that may serve as central nervous system stimulants for attention deficit-hyperactivity disorder, including dexmethylphenidate, no studies have addressed whether there is an association between attention deficit-hyperactivity disorder treatments and PAH in children.…”

Section: Isolated Pahmentioning

confidence: 99%

Pediatric Pulmonary Hypertension

Abman¹,

Hansmann²,

Archer³

et al. 2015

Circulation

916

405

View full text Add to dashboard Cite

Abstract-Pulmonary hypertension is associated with diverse cardiac, pulmonary, and systemic diseases in neonates, infants, and older children and contributes to significant morbidity and mortality. However, current approaches to caring for pediatric patients with pulmonary hypertension have been limited by the lack of consensus guidelines from experts in the field. In a joint effort from the American Heart Association and American Thoracic Society, a panel of experienced clinicians and clinician-scientists was assembled to review the current literature and to make recommendations on the diagnosis, evaluation, and treatment of pediatric pulmonary hypertension. This publication presents the results of extensive literature reviews, discussions, and formal scoring of recommendations for the care of children with pulmonary hypertension. Key Words: AHA Scientific Statements ◼ bronchopulmonary dysplasia ◼ congenital diaphragmatic hernia ◼ congenital heart disease ◼ genetics ◼ persistent pulmonary hypertension of the newborn ◼ sickle cell disease © 2015 by the American Heart Association, Inc., and the American Thoracic Society.Circulation is available at http://circ.ahajournals.org DOI: 10.1161/CIR.0000000000000329 †Deceased. The American Heart Association and the American Thoracic Society make every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.This document was approved by the American Heart Association Science Advisory and Coordinating Committee on May 12, 2015, the American Heart Association Executive Committee on July 22, 2015, and the American Thoracic Society on July 24, 2015.The online-only Data Supplement is available with this article at http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIR.0000000000000329/-/DC1. The American Heart Association requests that this document be cited as follows: Abman SH, Hansmann G, Archer SL, Ivy DD, Adatia I, Chung WK, Hanna BD, Rosenzweig EB, Raj JU, Cornfield D, Stenmark KR, Steinhorn R, Thébaud B, Fineman JR, Kuehne T, Feinstein JA, Friedberg MK, Earing M, Barst RJ, Keller RL, Kinsella JP, Mullen M, Deterding R, Kulik T, Mallory G, Humpl T, Wessel DL; on behalf of the American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Clinical Cardiology, Council on Cardiovascular Disease in the Young, Council on Cardiovascular Radiology and Intervention, Council on Cardiovascular Surgery and Anesthesia, and the American Thoracic Society. Pediatric pulmonary hypertension: guidelines from the American Heart Association and American Thoracic Society. Circulation. 2015;132:2037-2099 Copies: This document is available on the World Wide Web site of the American Heart Associat...

show abstract

Section: Isolated Pahmentioning

confidence: 99%

Pediatric Pulmonary Hypertension

Abman¹,

Hansmann²,

Archer³

et al. 2015

Circulation

916

405

View full text Add to dashboard Cite

show abstract

“…A range of 59-70% of HIV-PAH cases are reported to be in individuals engaging in IVDU (14)(15)(16). Although the abuse of cocaine and other stimulants may be an independent risk factor in the development of pulmonary vascular injury (17)(18)(19)(20), HIV-1 and cocaine interplay in the host might be involved in the exacerbation of pulmonary vasculature dysfunction, leading to the higher incidence of PAH in HIVinfected individuals with IVDU as a risk factor. Clearly, HIV and cocaine each have the capacity to orchestrate endothelial cell injury and dysfunction that may lead to abnormal smooth muscle cell (SMC) proliferation/migration and subsequent vascular remodeling.…”

mentioning

confidence: 99%

Effect of Cocaine on Human Immunodeficiency Virus–Mediated Pulmonary Endothelial and Smooth Muscle Dysfunction

Dhillon

Xue

et al. 2011

Am J Respir Cell Mol Biol

View full text Add to dashboard Cite

“…Furthermore, a report documenting acute severe PAH in the absence of left ventricular heart failure or pulmonary embolism shortly after the use of IV cocaine was published by Collazos et al (9). Interestingly, PAH in this case report resolved 2 days post-drug cessation.…”

Section: Cocainementioning

confidence: 55%

Drugs and toxins-associated pulmonary arterial hypertension: lessons learned and challenges ahead

Perez

Kudelko

Snook

et al. 2010

International Journal of Clinical Practice

View full text Add to dashboard Cite

Since the identification of the link between pulmonary arterial hypertension (PAH) and exposure to certain drugs and toxins nearly fifty years ago, the expanding landscape of available pharmaceuticals and illicit drugs is further fueling this association. While some causative agents in drugs and toxins associated PAH (D&T-APAH) have been identified, little is known about the exact biology and clinical implications of the disease. In this review, we discuss the historical evidence that links PAH with exposure to anorexinogens, cocaine, and methamphetamines and concentrate on what is known about potential pathogenesis, clinical manifestations, and current management. We conclude that future research should focus on studies looking at clinical outcome and susceptibility factors.

show abstract

Acute, reversible pumonary hypertension associated with cocaine use

Cited by 29 publications

References 12 publications

Pediatric Pulmonary Hypertension

Pediatric Pulmonary Hypertension

Effect of Cocaine on Human Immunodeficiency Virus–Mediated Pulmonary Endothelial and Smooth Muscle Dysfunction

Drugs and toxins-associated pulmonary arterial hypertension: lessons learned and challenges ahead

Contact Info

Product

Resources

About